Welcome to our dedicated page for Zimmer Biomet news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet stock.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is a global medical technology company focused on musculoskeletal health, orthopedic implants and digital and robotic technologies. This news page aggregates company announcements, press releases and market-facing updates so readers can follow how Zimmer Biomet develops and commercializes its orthopedic, trauma and digital care offerings.
Recent news highlights include earnings announcements and conference call webcasts, where Zimmer Biomet reports quarterly financial results and discusses performance across product categories such as knees, hips, sports medicine, extremities, trauma and technology and data, bone cement and surgical. The company also issues updates on its capital allocation, including quarterly cash dividends approved by its Board of Directors.
Zimmer Biomet frequently announces product and technology milestones. Examples include U.S. FDA 510(k) clearance for an enhanced version of its ROSA Knee robotic technology, FDA Breakthrough Device Designation for an iodine-treated total hip replacement system, and launches of new foot and ankle trauma solutions through its Paragon 28 business. The company also reports collaborations and integrations, such as the use of mobility intelligence technology within its mymobility care management platform, and highlights its broader connected care strategy linking robotics, digital platforms and analytics.
Investors and observers can also find updates on Zimmer Biomet’s participation in major healthcare and investor conferences, as well as news related to acquisitions like the merger with Monogram Technologies Inc. Bookmark this page to review the latest official communications from Zimmer Biomet on its orthopedic portfolio, digital and robotic technologies, financial disclosures and strategic initiatives.
Zimmer Biomet Holdings (ZBH) will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 10:30 a.m. ET, and at the J.P. Morgan 13th Annual U.S. All Stars Conference on September 20, 2022, at 9:00 a.m. ET. The presentations will be available via a live webcast on Zimmer Biomet's Investor Relations website, with recordings accessible afterward. Zimmer Biomet is known for its innovative medical technology solutions aimed at improving patient mobility and health, supported by over 90 years of industry leadership.
Zimmer Biomet announced a quarterly cash dividend of $0.24 per share for Q3 2022, payable on October 31, 2022. This dividend will benefit stockholders of record as of September 30, 2022, demonstrating the company's commitment to returning value to its shareholders. The company continues to position itself as a leader in the medical technology sector, focusing on enhancing patient experiences through innovation.
Zimmer Biomet reported Q2 2022 net sales of $1.782 billion, a 1.0% increase year-over-year and a 6.0% rise on a constant currency basis. Diluted EPS was $0.73, with adjusted EPS at $1.82. The company attributed its performance to a stronger-than-expected COVID recovery and strategic execution. Full-year 2022 guidance was raised, now forecasting revenue change between (1.0)% and 1.0% and adjusted diluted EPS of $6.70 to $6.90. The launch of AI capabilities in their Omni Suite was also highlighted.
Zimmer Biomet (ZBH) and Hospital for Special Surgery (HSS) have announced a three-year collaboration to establish the HSS/Zimmer Biomet Innovation Center for Artificial Intelligence in Robotic Joint Replacement. This first-of-its-kind partnership will focus on developing AI-based decision support tools for robotic-assisted joint surgeries, enhancing clinical outcomes through data-driven insights. The initiative leverages the expertise of HSS and Zimmer Biomet's robotics and AI capabilities, integrating these tools into their ROSA system to improve patient care.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) has announced a conference call to discuss its second quarter earnings on August 2, 2022, at 8:30 a.m. ET. Investors can access the live webcast via the company's Investor Relations website, with a news release detailing the results available at 6:30 a.m. ET on the same day. The call will also be archived for future listening.
Zimmer Biomet continues to focus on improving mobility and health through its innovative medical technologies.
Zimmer Biomet Holdings has launched an independent 501(c)(3) organization named Movement is Life, Inc., aimed at addressing musculoskeletal health disparities among underserved populations. Founded in 2010, Movement is Life will focus on education, early intervention, and advocacy. The Zimmer Biomet Foundation has committed multi-million dollar support for operational costs. The inaugural Board consists of notable healthcare leaders, with Millicent Gorham appointed as Executive Director, ensuring continuity of current programs and expanding partnerships to enhance the coalition's impact.
Zimmer Biomet announced the appointment of Keri P. Mattox as Chief Communications and Administration Officer, effective May 26, 2022. In her expanded role, she will oversee the company's Environmental, Social and Governance (ESG) strategy alongside enhancing CEO visibility and engagement. Mattox has been with Zimmer Biomet since January 2020, previously serving as Senior Vice President of Investor Relations and Chief Communications Officer. Her experience includes roles at W2O Group and AmerisourceBergen, reinforcing a strategic focus on integrating communications and investor relations.
Zimmer Biomet Holdings, a global leader in medical technology, announced a quarterly cash dividend of $0.24 per share for Q2 2022. This dividend is payable on or about July 29, 2022, to stockholders of record as of the close of business on June 27, 2022. The company continues to emphasize its commitment to enhancing patient mobility and health through innovative products and integrated digital technologies. With over 90 years of experience, Zimmer Biomet aims to deliver high-quality solutions worldwide.
Zimmer Biomet appointed Paul Stellato as Vice President, Controller, and Chief Accounting Officer. Stellato brings over two decades of financial experience, previously serving as Vice President of Finance at Xylem Inc. His expertise spans controllership, FP&A, investor relations, and internal audit, bolstering Zimmer Biomet's leadership team. Suky Upadhyay, CFO, expressed confidence in Stellato's ability to advance the company's financial strategies. With a strong educational background, including a Bachelor’s from Villanova University and an MBA from NYU Stern, Stellato is also a Certified Public Accountant.
Zimmer Biomet introduced new artificial intelligence capabilities in its Omni Suite, aimed at enhancing surgical workflow efficiency. This intelligent operating room solution automates manual tasks, providing real-time workflow metrics through automatic recognition of key milestones, such as patient entry and anesthesia timing. The AI feature complements the existing ZBEdge technology, enhancing patient outcomes and surgical experiences. Currently available in the United States, the Omni Suite demonstrates Zimmer Biomet's commitment to innovation in medical technology.